SLC5A2 and congestive heart failure: New users of SGLT-2 inhibitors had a greater burden of renal disease and congestive heart failure compared with new users of other glucose-lowering therapies—findings that align with guideline-driven preferential use of SGLT-2i in these high-risk populations30.